Studies

Tirzepatide is the first dual long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist indicated for the treatment of type 2 diabetes in adults, for reducing excess body weight and maintaining lon…

The anorectic peptide-based obesity management medications (OMM) have dominated the treatment of obesity over the last decade. This review analyses the evidence that has laid the ground for the three most frequently used drugs (liraglutide, semagluti…

AIMS: In SURMOUNT-5, tirzepatide led to greater body weight (BW) reduction versus semaglutide in adults with obesity without T2D. Health-related quality of life (HRQoL) with tirzepatide versus semaglutide in SURMOUNT-5 was evaluated. MATERIALS AND ME…

OBJECTIVE: This post hoc analysis of SURMOUNT trials assessed the association of baseline physical function (PF) with obesity-related complications (ORCs), efficacy measures, and PF. The mechanism of tirzepatide-led improvements in PF was evaluated.…

BACKGROUND: The comparative gastrointestinal safety across glucagon-like peptide-1 receptor agonists and tirzepatide is still unclear. OBJECTIVE: To compare the risk for severe gastrointestinal adverse events across dulaglutide, subcutaneous semaglut…

OBJECTIVE: To investigate the impact of estrogen deficiency on metabolic dysfunction-associated steatotic liver disease progression and evaluate the therapeutic potential of tirzepatide (Tzp), a dual glucose-dependent insulinotropic polypeptide/gluca…

Cardiovascular outcome trials of the incretin-based medicines tirzepatide and semaglutide have shown benefits in populations with varying levels of cardiovascular risk. However, without direct head-to-head comparisons, treatment decisions rely on ind…

BACKGROUND: Cardiovascular disease (CVD) and chronic kidney disease (CKD) frequently coexist, with obesity and type 2 diabetes (T2D) being major contributors to adverse outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and tirzepatide ha…

The impact of GLP-1 or GIP/GLP-1 receptor agonist use on unscheduled care is not well-described. We conducted a prospective, observational study using opportunistic screening by clinicians as a first step to understanding the effect of GLP-1 or GIP/G…

OBJECTIVES: This study aimed to test whether tirzepatide, a dual GLP-1RA/GIP agonist, approved for weight management, would be associated with lowered serum uric acid (SUA) levels via its weight reduction properties. METHODS: A post hoc analysis of t…

The emergence of GLP-1 receptor agonists, such as semaglutide and tirzepatide, has transformed the landscape of weight management and diabetes treatment. Initially developed for type 2 diabetes mellitus, these medications have gained widespread popul…

INTRODUCTION: Tirzepatide is recommended as a first-line injectable for people with type 2 diabetes (T2D), but there is a paucity of data on the use of basal insulin after tirzepatide in this population. This study aimed to evaluate glycemic control…

OBJECTIVE: Overweight and obesity are prevalent in type 1 diabetes and contribute to cardiovascular risk. Tirzepatide, a gastric inhibitory polypeptide and glucagon-like peptide 1 receptor coagonist, has not been studied in type 1 diabetes. RESEARCH…